MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318672 | Name: Rivastigmine Tartrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rivastigmine tartrate is an orally active and potent cholinesterase (ChE) inhibitor. Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia, particularly Alzheimer's and dementia due to Parkinson's disease.

Chemical Structure

Rivastigmine Tartrate
Rivastigmine Tartrate
CAS# 129101-54-8 (tartrate)

Theoretical Analysis

MedKoo Cat#: 318672

Name: Rivastigmine Tartrate

CAS#: 129101-54-8 (tartrate)

Chemical Formula: C18H28N2O8

Exact Mass: 0.0000

Molecular Weight: 400.42

Elemental Analysis: C, 53.99; H, 7.05; N, 7.00; O, 31.96

Price and Availability

Size Price Availability Quantity
200mg USD 250.00
500mg USD 450.00
1g USD 650.00
2g USD 950.00
5g USD 1,650.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
123441-03-2 (free base) 129101-54-8 (tartrate)
Synonym
ENA713; ENA 713; ENA-713; SDZ-ENA 713; SDZ-ENA713; SDZ-ENA-713; Rivastigmine Tartrate; Rivastigmine bitartrate.
IUPAC/Chemical Name
(2R,3R)-2,3-dihydroxybutanedioic acid;[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
InChi Key
GWHQHAUAXRMMOT-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)
SMILES Code
CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C.C(C(C(=O)O)O)(C(=O)O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in water
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Rivastigmine tartrate inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier.
In vitro activity:
The results from this study show that rivastigmine affords neuroprotection through a mechanism that is likely unrelated to AChE inhibition. For rivastigmine, the exact mechanism is unknown. PI3K-Akt blocker 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY294002) did not reverse the effects of rivastigmine. Reference: J Pharmacol Exp Ther. 2005 Dec;315(3):1346-53. https://pubmed.ncbi.nlm.nih.gov/16144975/
In vivo activity:
In male rats, rivastigmine administration alleviated biochemical and histological parameters and partially ameliorated Botulinum toxin (Botox)-induced impairments. Rivastigmine could be a suitable protective approach for side effects of Botox in the hippocampus.The hippocampal cholinergic system plays a significant role in memory and learning that could be affected by Botox. Reference: Neurotoxicology. 2023 Jul 26;98:29-38. https://pubmed.ncbi.nlm.nih.gov/37507053/
Solvent mg/mL mM
Solubility
Water 50.0 124.87
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 400.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Terada K, Migita K, Matsushima Y, Sugimoto Y, Kamei C, Matsumoto T, Mori M, Matsunaga K, Takata J, Karube Y. Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. PLoS One. 2018 Dec 17;13(12):e0209250. doi: 10.1371/journal.pone.0209250. PMID: 30557385; PMCID: PMC6296549. 2. Arias E, Gallego-Sandín S, Villarroya M, García AG, López MG. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther. 2005 Dec;315(3):1346-53. doi: 10.1124/jpet.105.090365. Epub 2005 Sep 6. PMID: 16144975. 3. Mehri K, Oskuye ZZ, Nassireslami E, Karami E, Parvizi MR. Rivastigmine ameliorates botulinum-induced hippocampal damage and spatial memory impairment in male rats. Neurotoxicology. 2023 Jul 26;98:29-38. doi: 10.1016/j.neuro.2023.07.004. Epub ahead of print. PMID: 37507053. 4. Gupta P, Tiwari S, Singh A, Pal A, Mishra A, Singh S. Rivastigmine attenuates the Alzheimer's disease related protein degradation and apoptotic neuronal death signalling. Biochem J. 2021 Apr 16;478(7):1435-1451. doi: 10.1042/BCJ20200754. Erratum in: Biochem J. 2022 Jun 17;479(11):1147. PMID: 33660768.
In vitro protocol:
1. Terada K, Migita K, Matsushima Y, Sugimoto Y, Kamei C, Matsumoto T, Mori M, Matsunaga K, Takata J, Karube Y. Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. PLoS One. 2018 Dec 17;13(12):e0209250. doi: 10.1371/journal.pone.0209250. PMID: 30557385; PMCID: PMC6296549. 2. Arias E, Gallego-Sandín S, Villarroya M, García AG, López MG. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther. 2005 Dec;315(3):1346-53. doi: 10.1124/jpet.105.090365. Epub 2005 Sep 6. PMID: 16144975.
In vivo protocol:
1. Mehri K, Oskuye ZZ, Nassireslami E, Karami E, Parvizi MR. Rivastigmine ameliorates botulinum-induced hippocampal damage and spatial memory impairment in male rats. Neurotoxicology. 2023 Jul 26;98:29-38. doi: 10.1016/j.neuro.2023.07.004. Epub ahead of print. PMID: 37507053. 2. Gupta P, Tiwari S, Singh A, Pal A, Mishra A, Singh S. Rivastigmine attenuates the Alzheimer's disease related protein degradation and apoptotic neuronal death signalling. Biochem J. 2021 Apr 16;478(7):1435-1451. doi: 10.1042/BCJ20200754. Erratum in: Biochem J. 2022 Jun 17;479(11):1147. PMID: 33660768.
1: Wesnes K. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease. Drugs Today (Barc). 2007 Jun;43(6):349-59. doi: 10.1358/dot.2007.43.6.1107987. PMID: 17612707. 2: Arora D, Bhatt S, Kumar M, Verma R, Taneja Y, Kaushal N, Tiwari A, Tiwari V, Alexiou A, Albogami S, Alotaibi SS, Mittal V, Singla RK, Kaushik D, Batiha GE. QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics. Front Aging Neurosci. 2022 Aug 11;14:960246. doi: 10.3389/fnagi.2022.960246. Retraction in: Front Aging Neurosci. 2024 Mar 28;16:1399271. doi: 10.3389/fnagi.2024.1399271. PMID: 36034142; PMCID: PMC9407039. 3: Nieto RA, Deardorff WJ, Grossberg GT. Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease. Expert Opin Pharmacother. 2016;17(6):861-70. doi: 10.1517/14656566.2016.1159296. PMID: 26918774. 4: Frontiers Editorial Office. Retraction: QbD-based rivastigmine tartrate- loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics. Front Aging Neurosci. 2024 Mar 28;16:1399271. doi: 10.3389/fnagi.2024.1399271. PMID: 38605858; PMCID: PMC11007542. 5: Shamsi A, Mohammad T, Anwar S, Alajmi MF, Hussain A, Hassan MI, Ahmad F, Islam A. Probing the interaction of Rivastigmine Tartrate, an important Alzheimer's drug, with serum albumin: Attempting treatment of Alzheimer's disease. Int J Biol Macromol. 2020 Apr 1;148:533-542. doi: 10.1016/j.ijbiomac.2020.01.134. Epub 2020 Jan 16. PMID: 31954794. 6: Torabi SJ, Mohebali A, Abdouss M, Shakiba M, Abdouss H, Ramakrishna S, Teo YS, Jafari I, Rezvani Ghomi E. Synthesis and characterization of a novel molecularly imprinted polymer for the controlled release of rivastigmine tartrate. Mater Sci Eng C Mater Biol Appl. 2021 Sep;128:112273. doi: 10.1016/j.msec.2021.112273. Epub 2021 Jun 24. PMID: 34474832. 7: Shamsi A, Anwar S, Mohammad T, Alajmi MF, Hussain A, Rehman MT, Hasan GM, Islam A, Hassan MI. MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer's Disease Therapy. Biomolecules. 2020 May 20;10(5):789. doi: 10.3390/biom10050789. PMID: 32443670; PMCID: PMC7277793. 8: Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther. 2003 Jun;25(6):1634-53. doi: 10.1016/s0149-2918(03)80160-1. PMID: 12860489. 9: Waseem R, Shamsi A, Mohammad T, Alhumaydhi FA, Kazim SN, Hassan MI, Ahmad F, Islam A. Multispectroscopic and Molecular Docking Insight into Elucidating the Interaction of Irisin with Rivastigmine Tartrate: A Combinational Therapy Approach to Fight Alzheimer's Disease. ACS Omega. 2021 Mar 8;6(11):7910-7921. doi: 10.1021/acsomega.1c00517. PMID: 33778302; PMCID: PMC7992156. 10: Shamsi A, Mohammad T, Khan MS, Shahwan M, Husain FM, Rehman MT, Hassan MI, Ahmad F, Islam A. Unraveling Binding Mechanism of Alzheimer's Drug Rivastigmine Tartrate with Human Transferrin: Molecular Docking and Multi-Spectroscopic Approach towards Neurodegenerative Diseases. Biomolecules. 2019 Sep 17;9(9):495. doi: 10.3390/biom9090495. PMID: 31533274; PMCID: PMC6770857. 11: Shah SK, Krueger PM. Unsubstantiated superiority claims for rivastigmine tartrate. J Am Osteopath Assoc. 2006 Oct;106(10):589-90; author reply 590. PMID: 17122027. 12: Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004 Mar;19(3):165-9. PMID: 15119476. 13: Lipp L, Sharma D, Banerjee A, Singh J. In Vitro and in Vivo Optimization of Phase Sensitive Smart Polymer for Controlled Delivery of Rivastigmine for Treatment of Alzheimer's Disease. Pharm Res. 2020 Jan 15;37(3):34. doi: 10.1007/s11095-020-2757-6. PMID: 31942651; PMCID: PMC6996875. 14: Bayes M, Rabasseda X, Prous JR. Gateways to Clinical Trials. June 2002. Methods Find Exp Clin Pharmacol. 2002 Jun;24(5):291-327. PMID: 12168506. 15: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29. PMID: 12616965. 16: Patel KS, Dharamsi A, Priya M, Jain S, Mandal V, Girme A, Modi SJ, Hingorani L. Saffron (Crocus sativus L.) extract attenuates chronic scopolamine-induced cognitive impairment, amyloid beta, and neurofibrillary tangles accumulation in rats. J Ethnopharmacol. 2024 May 23;326:117898. doi: 10.1016/j.jep.2024.117898. Epub 2024 Feb 8. PMID: 38341114. 17: Avachat AM, Oswal YM, Gujar KN, Shah RD. Preparation and characterization of rivastigmine loaded human serum albumin (HSA) nanoparticles. Curr Drug Deliv. 2014;11(3):359-70. doi: 10.2174/15672018113109990050. PMID: 24893995. 18: Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010 Oct;76(2):189-99. doi: 10.1016/j.ejpb.2010.07.007. Epub 2010 Jul 15. PMID: 20637869. 19: Ellis JM. Cholinesterase inhibitors in the treatment of dementia. J Am Osteopath Assoc. 2005 Mar;105(3):145-58. PMID: 15863734. 20: Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol. 2000 Mar;7(2):159-69. doi: 10.1046/j.1468-1331.2000.00046.x. PMID: 10809936.

View History

GNF-1331

GNF-1331